Avanafil

Definition

An orally available phosphodiesterase type 5 (PDE5) inhibitor with vasodilatory activity. Avanafil selectively inhibits PDE5, thus inhibiting the degradation of cyclic guanosine monophosphate (cGMP) found in the smooth muscle of the corpus cavernosa of the penis. The inhibition of cGMP degradation results in prolonged muscle relaxation, vasodilation, and blood engorgement of the corpus cavernosa, thereby prolonging penile erection.

Also known as (S)-4-(3-Chloro-4-methoxybenzylamino)-2-(2-hydroxymethylpyrrolidin-1-yl)-N-pyrimidin-2-ylmethyl-5-pyrimidinecarboxamide, AVANAFIL, Stendra, TA 1790, TA-1790 — per NCIT

Also identified as

• ATC G04BE10 per RXNORM
• NCIT NCIT:C74354 per NCIT
• SCTID 703956007 per RXNORM
• SCTID 703957003 per RXNORM
• UNII DR5S136IVO per RXNORM

Indications